Pfizer's supply chain exhibits meaningful concentration risk, particularly in Active Pharmaceutical Ingredient (API) sourcing. Analysis indicates substantial supplier bargaining power due to concentrated API manufacturers, primarily located in Asia. While specific supplier names and percentage dependencies are not disclosed in the 10-K FY2025, the pharmaceutical industry standard suggests top-5 API suppliers often represent 40-60% of total API spend for large-cap pharma companies.

The high switching costs identified in our evidence review reinforce the stickiness of current vendor relationships. This dynamic supports the stable Gross Margin of 74.3% observed in 2025 but reduces flexibility to pivot sourcing strategies during geopolitical tensions or trade policy shifts. The Current Assets contraction of 14.8% from $50.36B (2024) to $42.90B (2025) may indicate inventory optimization, but also reduces buffer stock that could mitigate supply disruptions.

Single points of failure likely exist in sterile fill-finish capacity for injectable products and biologics contract manufacturing organizations (CMOs). These facilities require extensive regulatory validation, making rapid substitution impractical. Management's governance mechanism for reviewing supply chain risks, identified through analysis, will be critical to identifying and mitigating these vulnerabilities before they impact production continuity.

Pfizer's global manufacturing footprint creates diversified geographic exposure but also introduces geopolitical and regulatory risks. While the 10-K FY2025 does not break down manufacturing locations by region, industry analysis suggests approximately 30-40% of API production for U.S. pharmaceutical companies originates from China and India. Analysis notes regulatory risks regarding foreign entities that could limit participation in supply chains for prohibited foreign entities under potential new trade restrictions.

The Goodwill increase to $71.26B from $68.53B year-over-year hints at M&A activity that may include supply chain vertical integration or geographic diversification. Such acquisitions could be strategic moves to secure API sources or manufacturing capacity amidst global supply chain fragmentation. However, integration of these assets must be monitored for impact on SG&A, which currently sits at 22.0% of Revenue.

Tariff exposure remains a wildcard for future cost structures. While not yet reflected in the 2025 financials, compliance with potential new restrictions could force costly supply chain reconfiguration. Pfizer's scale likely mitigates individual supplier power, yet industry-wide API concentration remains a systemic risk that transcends company-specific procurement strategies. The Free Cash Flow of $9.08B provides adequate funding for potential supply chain restructuring without excessive leverage.